Table 1. Patient tumour and treatment characteristics (N=326).

	Patient age group
	70–74yrs		75–84yrs		⩾85yrs		All patients
Tumour and treatment characteristics	N	%	N	%	N	%	N	%
T stage
T1	49	43%	78	44%	12	43%	139	43%
T2	51	44%	67	38%	16	41%	134	41%
T3	9	8%	17	10%	2	9%	28	9%
T4	0	0%	3	2%	0	1%	3	1%
Unknown	6	5%	12	7%	4	7%	22	7%
N stage
Node +	33	29%	58	33%	10	31%	101	31%
Node −	76	66%	108	61%	22	63%	206	63%
Node status unknown	6	5%	11	6%	2	6%	19	6%
Grade
I	12	10%	21	12%	6	12%	39	12%
II	71	62%	85	48%	18	53%	174	53%
III	30	26%	68	38%	10	33%	108	33%
Unknown	2	2%	3	2%	0	2%	5	2%
Histology
IDC	81	70%	151	85%	27	79%	259	79%
ILC	23	20%	13	7%	3	12%	39	12%
Other	5	4%	5	3%	1	3%	11	3%
Unknown	6	5%	8	5%	3	5%	17	5%
Receptor status
ER status
ER+	104	90%	153	86%	28	87%	285	87%
ER−	11	10%	24	14%	6	13%	41	13%
HER2 status
HER2+	15	13%	27	15%	4	14%	46	14%
HER2−	95	83%	144	81%	28	82%	267	82%
Unknown	5	4%	6	3%	2	4%	13	4%
Surgery
Mastectomy	41	36%	56	32%	10	29%	107	33%
WLE	70	61%	113	64%	22	65%	205	63%
No surgery at all	4	3%	6	3%	2	6%	12	4%
Unknown	0	0%	2	1%	0	0%	2	1%
Axillary surgery	102	89%	159	90%	26	76%	287	88%
Adjuvant radiotherapy
Yes	79	69%	125	71%	25	74%	229	70%
No	32	28%	50	28%	9	26%	91	28%
Unknown	4	3%	2	1%	0	0%	6	2%
WLE+adjuvant radiotherapy	63	90%	103	91%	19	86%	185	90%a
Adjuvant chemotherapy
Yes	17	15%	40	23%	8	24%	65	20%
No	95	83%	136	77%	26	76%	257	79%
Unknown	3	3%	1	1%	0	0%	4	1%
HER2-positive patients receiving Trastuzumab+Chemotherapyb	7	47%	18	67%	4	100%	29	63%
Endocrine therapy
ER-positive patients receiving adjuvant endocrine therapy	95	91%	137	90%	27	96%	259	91%

Abbreviations: ER=oestrogen receptor; HER2 = human epidermal growth factor receptor 2; IDC= Infiltrating ductal carcinoma; ILC= Infiltrating lobular carcinoma; WLE=wide local excision.

^a90%=185 of the 205 patients who underwent WLE and subsequently received adjuvant radiotherapy.

^bFour patients received Trastuzumab without concomitant chemotherapy: 1 in the 70–74 years age group, 2 in the 75–84 years age group, and 1 in the ⩾85yr group.